ERBB2 and neoplasm: The mutations in the p53 tumor suppressor, upregulation of heterodimerization partners, such as HER3 and EGFR, and activation of downstream targets, such as Src kinase, were often found in HER2+ breast cancer patients and promoted tumorigenesis [11].